WO2023048684A2 - The tablet comprising macitentan - Google Patents
The tablet comprising macitentan Download PDFInfo
- Publication number
- WO2023048684A2 WO2023048684A2 PCT/TR2022/051014 TR2022051014W WO2023048684A2 WO 2023048684 A2 WO2023048684 A2 WO 2023048684A2 TR 2022051014 W TR2022051014 W TR 2022051014W WO 2023048684 A2 WO2023048684 A2 WO 2023048684A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- sodium
- tablet
- tablet according
- macitentan
- Prior art date
Links
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 229960001039 macitentan Drugs 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 229920002785 Croscarmellose sodium Polymers 0.000 claims abstract description 20
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960001681 croscarmellose sodium Drugs 0.000 claims abstract description 20
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims abstract description 20
- 239000007884 disintegrant Substances 0.000 claims abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960000913 crospovidone Drugs 0.000 claims abstract description 5
- 229960000502 poloxamer Drugs 0.000 claims abstract description 5
- 229920001983 poloxamer Polymers 0.000 claims abstract description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 claims abstract description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 239000011230 binding agent Substances 0.000 claims description 17
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 16
- 229960001021 lactose monohydrate Drugs 0.000 claims description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 16
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 15
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 15
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 14
- 239000000945 filler Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000314 lubricant Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 9
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 8
- 239000000454 talc Substances 0.000 claims description 8
- 229910052623 talc Inorganic materials 0.000 claims description 8
- 229940033134 talc Drugs 0.000 claims description 8
- 235000012222 talc Nutrition 0.000 claims description 8
- 239000007888 film coating Substances 0.000 claims description 7
- 238000009501 film coating Methods 0.000 claims description 7
- 235000002639 sodium chloride Nutrition 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 239000007916 tablet composition Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920000193 polymethacrylate Polymers 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920001100 Polydextrose Polymers 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 4
- 229960001714 calcium phosphate Drugs 0.000 claims description 4
- 235000011010 calcium phosphates Nutrition 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229960001375 lactose Drugs 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 235000013856 polydextrose Nutrition 0.000 claims description 4
- 239000001259 polydextrose Substances 0.000 claims description 4
- 229940035035 polydextrose Drugs 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 238000005550 wet granulation Methods 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004373 Pullulan Substances 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 229940081735 acetylcellulose Drugs 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 2
- 235000010407 ammonium alginate Nutrition 0.000 claims description 2
- 239000000728 ammonium alginate Substances 0.000 claims description 2
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 claims description 2
- 229960004977 anhydrous lactose Drugs 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 229960003563 calcium carbonate Drugs 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229960002737 fructose Drugs 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000829 kaolin Drugs 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 229960001708 magnesium carbonate Drugs 0.000 claims description 2
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 229960000869 magnesium oxide Drugs 0.000 claims description 2
- 235000012245 magnesium oxide Nutrition 0.000 claims description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002160 maltose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 239000000196 tragacanth Substances 0.000 claims description 2
- 229940116362 tragacanth Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 229940074410 trehalose Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 10
- 239000003826 tablet Substances 0.000 description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 238000004090 dissolution Methods 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000001147 pulmonary artery Anatomy 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- 231100001125 band 2 compound Toxicity 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000036593 pulmonary vascular resistance Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 102100040611 Endothelin receptor type B Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940058799 opsumit Drugs 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Definitions
- the present invention relates to a tablet comprising macitentan or a pharmaceutically acceptable salt and at least one disintegrant and at least one the pharmaceutically acceptable excipients wherein disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, carboxymethyl cellulose, poloxamer or mixtures thereof.
- disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, carboxymethyl cellulose, poloxamer or mixtures thereof.
- the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the tablet.
- Pulmonary arterial hypertension is a disease that accumulates pulmonary artery endothelial cells, muscle layer and adventitia, which restricts pulmonary artery blood flow, which leads to increased pulmonary vascular resistance, progressive increase in pulmonary artery pressure, and finally causes the right heart A malignant cardiovascular disease of failure or even death. Its main feature is the gradual increase in pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP) caused by pulmonary artery obstruction, accompanied by irreversible pulmonary vascular remodeling. Patients with severe symptoms can cause right heart failure and death, with poor prognosis and high mortality.
- PVR pulmonary vascular resistance
- PAP pulmonary arterial pressure
- Macitentan is an endothelin receptor antagonist, which prevents endothelin (ET-1) from binding to ETA and ETB receptors, and exhibits high affinity and sustained occupancy in human pulmonary artery smooth muscle cells.
- Macitentan is the active ingredient marketed under the brand OPSUMIT® for the long-term treatment of pulmonary arterial hypertension.
- Macitentan is a BCS class II drug substance characterized by low solubility and high permeability. The poor solubility and low dissolution rate of poorly water-soluble drugs in the aqueous gastrointestinal fluids often cause insufficient bioavailability. It is known that for BCS class II drugs rate limiting step is drug release from the dosage form and solubility in the gastric fluid and not the absorption, so increasing the solubility in turn increases the bioavailability for BCS class II drugs.
- WO 2002053557 A1 application discloses macitentan and its preparation method.
- WO 2007031933 A1 application discloses solid oral pharmaceutical compositions of macitentan. The results hint that, of all the possibilities tested, the compositions evidencing better behaviour were the ones comprising a high dosage of lactose or lactose monohydrate as filler.
- the main object of the present invention relates to a tablet composition comprising macitentan which eliminates the problems of dissolution and bioavailability and provides additional advantages to the relevant field of art.
- Another object of the present invention is to provide a tablet composition which provides the desired stability.
- Another object of the present invention is to provide a composition which is characterized by excellent pharmacotechnical properties, such as flowability, compressibility and content uniformity.
- a tablet composition comprises macitentan or a pharmaceutically acceptable salt and at least one disintegrant and at least one the pharmaceutically acceptable excipients wherein; disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, carboxymethyl cellulose, poloxamer or mixtures thereof. Using said disintegrants provides adequate disintegrating properties for the tablets of the present invention but also it provides homogeneity of the active pharmaceutical ingredient which does not degrade to unwanted impurities.
- the disintegrant is croscarmellose sodium.
- the disintegrant is crospovidone. According to this embodiment of the present invention, the amount of disintegrants is 0.1% to 20.0% by weight of the total core tablet.
- the amount of disintegrants is 1.0% to 10.0% or preferably 1.0% to 5.0% by weight of the total core tablet.
- the amount of macitentan or a pharmaceutically acceptable salt is 5.0% to 25.0% or preferably 10.0% to 20.0% by weight of the total core tablet.
- macitentan is present in the form of amorphous.
- excipients provided in a formulation may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, absorption, bioavailability of an active agent. Macitentan may interact with several excipients. For this reason, the excipients which accompany an active agent have to be selected in a careful and conscious manner while a formulation) is developed.
- the formulations should have no physicochemical incompatibility between the active agent and the excipients.
- the pharmaceutically acceptable excipients are selected from the group comprising fillers, binders, surfactants, lubricants or mixtures thereof.
- Suitable fillers are selected from group comprising lactose monohydrate, microcrystalline cellulose, mannitol, lactose, pregelatinized starch, ammonium alginate, calcium carbonate, anhydrous lactose, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, fructose, glyceryl palmitostearate, kaolin, lactitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar sphericals, sulfobutylether beta-cyclodextrin, talc, tragacanth, trehalose, xylitol or mixtures thereof.
- the filler is lactose monohydrate or lactose or microcrystalline cellulose or mixtures thereof.
- the filler is lactose monohydrate and microcrystalline cellulose.
- lactose monohydrate is a filler which has the good flowability properties among the other fillers. In this invention, it further improves the disintegration of compositon as well as being a filler. In addition, it further enhances the compressibility by increasing the hardness of the tablet. According to this embodiment of the present invention, the amount of filler is 55.0% to 90.0% by weight of the total core tablet.
- the amount of filler is 70.0% to 85.0% by weight of the total core tablet.
- Suitable binders are selected from the group comprising polyvinylpyrrolidone, hydroxypropyl methylcellulose, croscarmellose sodium, cellulose acetate phthalate, starch, ethylcellulose, glyceryl behenate, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, magnesium aluminum silicate, maltodextrin, methylcellulose, polydextrose, polyethylene oxide, polymethacrylates, aluminia hydroxide, stearic acid, sucrose, polyoxyethilene-alkyl ethers, pullulan or mixtures thereof.
- the binder is polyvinylpyrrolidone or hydroxypropyl methylcellulose or mixtures thereof.
- the binder is polyvinylpyrrolidone.
- the binder is hydroxypropyl methylcellulose.
- the amount of binder is 0.1% to 15.0% by weight of the total core tablet.
- the amount of binder is 1.0% to 10.0%, preferably 1.0% to 7.0% by weight of the total core tablet.
- a surfactant is a substance that is generally a compound which lowers the surface tension between two liquids or between a liquid and a solid.
- Suitable surfactants are selected from the group comprising polysorbates, sodium lauryl sulphate, benzalconium chloride, docusate sodium, glyceryl esters, glyceryl monoleate, poloxamer, polyethylene alkyl ethers, polyglyceryl esters, polyoxyetylene esters, polyoxyetylene stearates, sodium stearate, hexadecyl pyridinium chloride or mixtures thereof.
- the surfactant is polysorbates.
- the amount of surfactant is 0.05% to 2.0% by weight of the total core tablet.
- a polysorbate included in a tablet according to the present invention will have a mean polymerisation degree of from 20 to 100 monomer units, and may in the present invention be polysorbate 80.
- polysorbate 80 at least one binder is dissolved in a solvent. Then, the solution comprising polysorbate 80 is mixed other excipients and active agent. This provides both the desired content uniformity and the desired dissolution profile. Also, this helps to provide the desired flowability and compressibility.
- Suitable lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, calcium stearate, zinc stearate, talc, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate or mixtures thereof.
- the lubricant is magnesium stearate or sodium stearyl fumarate.
- the lubricant is magnesium stearate.
- the lubricant is sodium stearyl fumarate.
- the amount of lubricant is 0.1% to 5.0% by weight of the total core tablet.
- the tablet is coated with film coating.
- Suitable film coating agent are selected from the group comprising polyvinyl alcohol (PVA), talc, titanium dioxide, glycerol, sodium lauryl sulphate, GMCC Type 1 (Glycerol monocaprylocaprate Type I) / Glycerol ester, polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, hydroxypropyl cellulose, polyethylene glycol (PEG), talc, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylpyrrolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, iron oxide or mixtures thereof or mixtures thereof.
- PVA polyvinyl alcohol
- talc titanium dioxide
- glycerol sodium lauryl sulphate
- the film coating agent are polyvinyl alcohol, talc, titanium dioxide, glycerol, sodium lauryl sulphate.
- the tablet is obtained by using a wet granulation method therefore, a simple and low-cost production method was employed.
- Wet granulation process efficiently counteracts segregation, so it can achieve good dissolution and disintegration properties. Also, the process provides a desired uniformity of content. Solvents are used in the process.
- the solvent is selected from the group comprising water, acetone, ethanol, isopropanol or mixtures thereof.
- water is used in the invention.
- the active ingredient is found in a low amount in the core tablet as a percentage.
- a binder solution is prepared with at least one surfactant and at least one binder and a solvent, then mixing with the mixture comprising active agents.
- a binder solution comprises polyvinylpyrrolidone and polisorbate (80).
- the tablet has a hardness between 50N to 70N, preferably between 55 N to 65N, this provides high chemical and mechanical stability, thus it is not brittle easily.
- the measurement is carried out on ERWEKA TBH125 in the present invention.
- a tablet comprises;
- a tablet comprises;
- Lactose monohydrate 11.0-35.0% by weight of Microcrystalline cellulose (PH 101) 0.1-20.0% by weight of Croscarmellose sodium
- a tablet comprises;
- a process for preparing tablet composition processed wet granulation comprises the following steps; a) Dissolving polysorbate and at least one binder (polyvinylpyrrolidone or HPMC) in water in homogenizer, b) Mixing macitentan, lactose monohydrate, microcrystalline cellulose (ph 101) and croscarmellose sodium, c) Adding the prepared granulation suspension at step (a) into powder mixture at step (b) and mixing to obtained wet granules, d) Drying and obtained dry granules, e) Sieving the dry granules, f) Adding croscarmellose sodium and microcrystalline cellulose then mixing, g) Adding at least one lubricant (magnesium stearate or Sodium stearyl fumarate) and mixing, h) Compressing to form of tablets,
- Film coating comprises polyvinyl alcohol, talc, titanium dioxide, glycerol, sodium lauryl sulfate.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a tablet comprising macitentan or a pharmaceutically acceptable salt and at least one disintegrant and at least one the pharmaceutically acceptable excipients wherein disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, carboxymethyl cellulose, poloxamer or mixtures thereof. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the tablet.
Description
DESCRIPTION
THE TABLET COMPRISING MACITENTAN
Field of the Invention
The present invention relates to a tablet comprising macitentan or a pharmaceutically acceptable salt and at least one disintegrant and at least one the pharmaceutically acceptable excipients wherein disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, carboxymethyl cellulose, poloxamer or mixtures thereof. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the tablet.
Background of the Invention
Pulmonary arterial hypertension (PAH) is a disease that accumulates pulmonary artery endothelial cells, muscle layer and adventitia, which restricts pulmonary artery blood flow, which leads to increased pulmonary vascular resistance, progressive increase in pulmonary artery pressure, and finally causes the right heart A malignant cardiovascular disease of failure or even death. Its main feature is the gradual increase in pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP) caused by pulmonary artery obstruction, accompanied by irreversible pulmonary vascular remodeling. Patients with severe symptoms can cause right heart failure and death, with poor prognosis and high mortality.
Macitentan is an endothelin receptor antagonist, which prevents endothelin (ET-1) from binding to ETA and ETB receptors, and exhibits high affinity and sustained occupancy in human pulmonary artery smooth muscle cells.
The chemical name of macitentan is N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4- pyrimidinyl]-N' -propylsulfamide and its chemical structure is shown in the Formula 1.
Formula I: Macitentan
Macitentan is the active ingredient marketed under the brand OPSUMIT® for the long-term treatment of pulmonary arterial hypertension.
Macitentan is a BCS class II drug substance characterized by low solubility and high permeability. The poor solubility and low dissolution rate of poorly water-soluble drugs in the aqueous gastrointestinal fluids often cause insufficient bioavailability. It is known that for BCS class II drugs rate limiting step is drug release from the dosage form and solubility in the gastric fluid and not the absorption, so increasing the solubility in turn increases the bioavailability for BCS class II drugs.
WO 2002053557 A1 application discloses macitentan and its preparation method.
WO 2007031933 A1 application discloses solid oral pharmaceutical compositions of macitentan. The results hint that, of all the possibilities tested, the compositions evidencing better behaviour were the ones comprising a high dosage of lactose or lactose monohydrate as filler.
In prior art, there are also several patents which disclose macitentan in tablet forms. However, despite the dissolution problem of macitentan, an effective formulation and method has not been disclosed.
There still remains a need in the art to provide an improved tablet composition of macitentan, having high solubility, dissolution rate, and accordingly a high bioavailability and a long-term stability which is also obtained by using an effective process.
Detailed Description of the Invention
The main object of the present invention relates to a tablet composition comprising macitentan which eliminates the problems of dissolution and bioavailability and provides additional advantages to the relevant field of art.
Another object of the present invention is to provide a tablet composition which provides the desired stability.
Another object of the present invention is to provide a composition which is characterized by excellent pharmacotechnical properties, such as flowability, compressibility and content uniformity.
According to this embodiment of the present invention, a tablet composition comprises macitentan or a pharmaceutically acceptable salt and at least one disintegrant and at least one the pharmaceutically acceptable excipients wherein; disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, carboxymethyl cellulose, poloxamer or mixtures thereof. Using said disintegrants provides adequate disintegrating properties for the tablets of the present invention but also it provides homogeneity of the active pharmaceutical ingredient which does not degrade to unwanted impurities.
According to this embodiment of the present invention, the disintegrant is croscarmellose sodium.
According to this embodiment of the present invention, the disintegrant is crospovidone.
According to this embodiment of the present invention, the amount of disintegrants is 0.1% to 20.0% by weight of the total core tablet.
According to this embodiment of the present invention, the amount of disintegrants is 1.0% to 10.0% or preferably 1.0% to 5.0% by weight of the total core tablet.
According to this embodiment of the present invention, the amount of macitentan or a pharmaceutically acceptable salt is 5.0% to 25.0% or preferably 10.0% to 20.0% by weight of the total core tablet.
According to this embodiment of the present invention, macitentan is present in the form of amorphous.
In general terms, excipients provided in a formulation may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, absorption, bioavailability of an active agent. Macitentan may interact with several excipients. For this reason, the excipients which accompany an active agent have to be selected in a careful and conscious manner while a formulation) is developed. The formulations should have no physicochemical incompatibility between the active agent and the excipients.
According to this embodiment of the present invention, the pharmaceutically acceptable excipients are selected from the group comprising fillers, binders, surfactants, lubricants or mixtures thereof.
Suitable fillers are selected from group comprising lactose monohydrate, microcrystalline cellulose, mannitol, lactose, pregelatinized starch, ammonium alginate, calcium carbonate, anhydrous lactose, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, fructose, glyceryl palmitostearate, kaolin, lactitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar sphericals, sulfobutylether beta-cyclodextrin, talc, tragacanth, trehalose, xylitol or mixtures thereof.
According to this embodiment of the present invention, the filler is lactose monohydrate or lactose or microcrystalline cellulose or mixtures thereof.
According to this embodiment of the present invention, the filler is lactose monohydrate and microcrystalline cellulose.
According to one embodiment, lactose monohydrate is a filler which has the good flowability properties among the other fillers. In this invention, it further improves the disintegration of compositon as well as being a filler. In addition, it further enhances the compressibility by increasing the hardness of the tablet.
According to this embodiment of the present invention, the amount of filler is 55.0% to 90.0% by weight of the total core tablet.
According to this embodiment of the present invention, the amount of filler is 70.0% to 85.0% by weight of the total core tablet.
Suitable binders are selected from the group comprising polyvinylpyrrolidone, hydroxypropyl methylcellulose, croscarmellose sodium, cellulose acetate phthalate, starch, ethylcellulose, glyceryl behenate, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, magnesium aluminum silicate, maltodextrin, methylcellulose, polydextrose, polyethylene oxide, polymethacrylates, aluminia hydroxide, stearic acid, sucrose, polyoxyethilene-alkyl ethers, pullulan or mixtures thereof.
According to this embodiment of the present invention, the binder is polyvinylpyrrolidone or hydroxypropyl methylcellulose or mixtures thereof.
According to this embodiment of the present invention, the binder is polyvinylpyrrolidone.
According to this embodiment of the present invention, the binder is hydroxypropyl methylcellulose.
According to this embodiment of the present invention, the amount of binder is 0.1% to 15.0% by weight of the total core tablet.
According to this embodiment of the present invention, the amount of binder is 1.0% to 10.0%, preferably 1.0% to 7.0% by weight of the total core tablet.
A surfactant is a substance that is generally a compound which lowers the surface tension between two liquids or between a liquid and a solid. Suitable surfactants are selected from the group comprising polysorbates, sodium lauryl sulphate, benzalconium chloride, docusate sodium, glyceryl esters, glyceryl monoleate, poloxamer, polyethylene alkyl ethers, polyglyceryl esters, polyoxyetylene esters, polyoxyetylene stearates, sodium stearate, hexadecyl pyridinium chloride or mixtures thereof.
According to this embodiment of the present invention, the surfactant is polysorbates.
According to this embodiment of the present invention, the amount of surfactant is 0.05% to 2.0% by weight of the total core tablet.
A polysorbate included in a tablet according to the present invention will have a mean polymerisation degree of from 20 to 100 monomer units, and may in the present invention be polysorbate 80.
According to this embodiment of the present invention, polysorbate 80 at least one binder is dissolved in a solvent. Then, the solution comprising polysorbate 80 is mixed other excipients and active agent. This provides both the desired content uniformity and the desired dissolution profile. Also, this helps to provide the desired flowability and compressibility.
Suitable lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, calcium stearate, zinc stearate, talc, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate or mixtures thereof.
According to this embodiment of the present invention, the lubricant is magnesium stearate or sodium stearyl fumarate.
According to this embodiment of the present invention, the lubricant is magnesium stearate.
According to this embodiment of the present invention, the lubricant is sodium stearyl fumarate.
According to this embodiment of the present invention, the amount of lubricant is 0.1% to 5.0% by weight of the total core tablet.
According to one embodiment of the present invention, the tablet is coated with film coating.
Suitable film coating agent are selected from the group comprising polyvinyl alcohol (PVA), talc, titanium dioxide, glycerol, sodium lauryl sulphate, GMCC Type 1 (Glycerol monocaprylocaprate Type I) / Glycerol ester, polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, hydroxypropyl cellulose, polyethylene glycol (PEG), talc, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylpyrrolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, iron oxide or mixtures thereof or mixtures thereof.
According to one embodiment of the present invention, the film coating agent are polyvinyl alcohol, talc, titanium dioxide, glycerol, sodium lauryl sulphate.
According to one embodiment of the present invention, the tablet is obtained by using a wet granulation method therefore, a simple and low-cost production method was employed. Wet granulation process efficiently counteracts segregation, so it can achieve good dissolution and disintegration properties. Also, the process provides a desired uniformity of content. Solvents are used in the process.
The solvent is selected from the group comprising water, acetone, ethanol, isopropanol or mixtures thereof. Preferably, water is used in the invention.
According to this embodiment of the present invention, the active ingredient is found in a low amount in the core tablet as a percentage. In the wet process, a binder solution is prepared with at least one surfactant and at least one binder and a solvent, then mixing with the mixture comprising active agents. When the film-coated tablet is prepared by the above-mentioned process it was seen that it does not lead to losses in the active agent or excipients during production and provides desired good content uniformity. It reflects that content uniformity play important role in the dissolution of the drug.
According to this embodiment of the present invention, a binder solution comprises polyvinylpyrrolidone and polisorbate (80).
According to this embodiment of the present invention, the tablet has a hardness between 50N to 70N, preferably between 55 N to 65N, this provides high chemical and mechanical stability, thus it is not brittle easily. The measurement is carried out on ERWEKA TBH125 in the present invention.
According to this embodiment of the present invention, a tablet comprises;
Macitentan
Lactose monohydrate
Microcrystalline cellulose (PH 101)
Croscarmellose sodium
Polyvinylpyrrolidone or HPMC
Polisorbate (80)
Sodium stearyl fumarate or magnesium stearate.
According to this embodiment of the present invention, a tablet comprises;
5.0-25.0% by weight of Macitentan
45.0-65.0% by weight of Lactose monohydrate 11.0-35.0% by weight of Microcrystalline cellulose (PH 101) 0.1-20.0% by weight of Croscarmellose sodium
I .0-7.0% by weight of Polyvinylpyrrolidone or HPMC 0.05-2.0% by weight of Polisorbate (80)
0.1 -5.0% by weight of Sodium stearyl fumarate or magnesium stearate.
According to this embodiment of the present invention, a tablet comprises;
I I.0-16.0% by weight of Macitentan
45.0-65.0% by weight of Lactose monohydrate
11.0-35.0% by weight of Microcrystalline cellulose (PH 101)
1.0-5.0% by weight of Croscarmellose sodium
1.0-7.0% by weight of Polyvinylpyrrolidone or HPMC
0.05-1.0% by weight of Polisorbate (80)
0.1 -3.0% by weight of Sodium stearyl fumarate or magnesium stearate.
According to another embodiment of the present invention, a process for preparing tablet composition processed wet granulation comprises the following steps; a) Dissolving polysorbate and at least one binder (polyvinylpyrrolidone or HPMC) in water in homogenizer, b) Mixing macitentan, lactose monohydrate, microcrystalline cellulose (ph 101) and croscarmellose sodium,
c) Adding the prepared granulation suspension at step (a) into powder mixture at step (b) and mixing to obtained wet granules, d) Drying and obtained dry granules, e) Sieving the dry granules, f) Adding croscarmellose sodium and microcrystalline cellulose then mixing, g) Adding at least one lubricant (magnesium stearate or Sodium stearyl fumarate) and mixing, h) Compressing to form of tablets,
I) Coating tablets with film coating.
A process for example 1 or 2 or 3 or 4; a) Dissolving polysorbate and at least one binder (polyvinylpyrrolidone or HPMC) in water in homogenizer, b) Mixing macitentan, lactose monohydrate, microcrystalline cellulose (ph 101) and croscarmellose sodium, c) Adding the prepared granulation suspension at step (a) into powder mixture at step (b) and mixing to obtained wet granules, d) Drying and obtained dry granules, e) Sieving the dry granules, f) Adding croscarmellose sodium and microcrystalline cellulose then mixing, g) Adding at least one lubricant (magnesium stearate or Sodium stearyl fumarate) and mixing, h) Compressing to form of tablets,
I) Coating tablets with film coating.
Film coating comprises polyvinyl alcohol, talc, titanium dioxide, glycerol, sodium lauryl sulfate.
Claims
CLAIMS A tablet composition comprising macitentan or a pharmaceutically acceptable salt and at least one disintegrant and at least one the pharmaceutically acceptable excipients wherein; disintegrants are selected from the group comprising croscarmellose sodium, crospovidone, carboxymethyl cellulose, poloxamer or mixtures thereof. The tablet according to claim 1 , wherein the disintegrant is croscarmellose sodium. The tablet according to claim 1, wherein the amount of macitentan or a pharmaceutically acceptable salt is 5.0% to 25.0% or preferably 10.0% to 20.0% by weight of the total core tablet. The tablet according to claim 1 , wherein the pharmaceutically acceptable excipients are selected from the group comprising fillers, binders, surfactants, lubricants or mixtures thereof. The tablet according to claim 4, wherein fillers are selected from group comprising lactose monohydrate, microcrystalline cellulose, mannitol, lactose, pregelatinized starch, ammonium alginate, calcium carbonate, anhydrous lactose, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, fructose, glyceryl palmitostearate, kaolin, lactitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar sphericals, sulfobutylether beta-cyclodextrin, talc, tragacanth, trehalose, xylitol or mixtures thereof. The tablet according to claim 5, wherein the amount of filler is 55.0% to 90.0% by weight of the total core tablet. The tablet according to claim 4, wherein binders are selected from the group comprising polyvinylpyrrolidone, hydroxypropyl methylcellulose, croscarmellose sodium, cellulose acetate phthalate, starch, ethylcellulose, glyceryl behenate, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, magnesium aluminum silicate, maltodextrin, methylcellulose, polydextrose, polyethylene oxide, polymethacrylates, aluminia hydroxide, stearic acid, sucrose, polyoxyethilene-alkyl ethers, pullulan or mixtures thereof. The tablet according to claim 7, wherein the binder is polyvinylpyrrolidone or hydroxypropyl methylcellulose or mixtures thereof. The tablet according to claim 4, wherein lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, calcium stearate, zinc stearate, talc, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate,
polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate or mixtures thereof.
10. The tablet according to claim 9, wherein the lubricant is magnesium stearate or sodium stearyl fumarate.
11. The tablet according to claim 1 , wherein the tablet has a hardness between 50N to 70N, preferably between 55 N to 65N.
12. The tablet according to claim 1 , wherein the tablet comprising;
Macitentan
Lactose monohydrate
Microcrystalline cellulose (PH 101)
Croscarmellose sodium
Polyvinylpyrrolidone or HPMC
Polisorbate (80)
Sodium stearyl fumarate or magnesium stearate.
13. The tablet according to claim 1 , wherein comprising
- 5.0-25.0% by weight of Macitentan
45.0-65.0% by weight of Lactose monohydrate
11.0-35.0% by weight of Microcrystalline cellulose (PH 101)
0.1-20.0% by weight of Croscarmellose sodium
I .0-7.0% by weight of Polyvinylpyrrolidone or HPMC
0.05-2.0% by weight of Polisorbate (80)
0.1 -5.0% by weight of Sodium stearyl fumarate or magnesium stearate.
14. The tablet according to claim 1 , wherein comprising
I I .0-16.0% by weight of Macitentan
45.0-65.0% by weight of Lactose monohydrate
11.0-35.0% by weight of Microcrystalline cellulose (PH 101 )
1.0-5.0% by weight of Croscarmellose sodium
1.0-7.0% by weight of Polyvinylpyrrolidone or HPMC
0.05-1.0% by weight of Polisorbate (80)
0.1 -3.0% by weight of Sodium stearyl fumarate or magnesium stearate.
15. A process for preparing tablet composition processed wet granulation comprising the following steps;
a) Dissolving polysorbate and at least one binder (polyvinylpyrrolidone or HPMC) in water in homogenizer, b) Mixing macitentan, lactose monohydrate, microcrystalline cellulose and croscarmellose sodium, c) Adding the prepared granulation suspension at step (a) into powder mixture at step (b) and mixing to obtained wet granules, d) Drying and obtained dry granules, e) Sieving the dry granules, f) Adding croscarmellose sodium and microcrystalline cellulose then mixing, g) Adding at least one lubricant (magnesium stearate or Sodium stearyl fumarate) and mixing, h) Compressing to form of tablets,
I) Coating tablets with film coating.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2021/014838 TR2021014838A2 (en) | 2021-09-22 | TABLET CONTAINING MASITENTAN | |
TR2021014838 | 2021-09-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023048684A2 true WO2023048684A2 (en) | 2023-03-30 |
WO2023048684A3 WO2023048684A3 (en) | 2023-06-22 |
Family
ID=85721370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2022/051014 WO2023048684A2 (en) | 2021-09-22 | 2022-09-20 | The tablet comprising macitentan |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023048684A2 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE14721256T1 (en) * | 2013-04-22 | 2017-03-16 | Sandoz Ag | PHARMACEUTICAL COMPOSITIONS WITH CRYSTALLINE MACITENTANE |
CN107913256A (en) * | 2016-10-08 | 2018-04-17 | 郑州泰丰制药有限公司 | A kind of macitentan oral disnitegration tablet for treating pulmonary hypertension and preparation method thereof |
CN112336693A (en) * | 2020-09-29 | 2021-02-09 | 南京斯泰尔医药科技有限公司 | Method for rapidly controlling and evaluating release of macitentan tablets |
-
2022
- 2022-09-20 WO PCT/TR2022/051014 patent/WO2023048684A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023048684A3 (en) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20160101720A (en) | Pharmaceutical compositions comprising azd9291 | |
US9408915B2 (en) | Tolvaptan solid dispersion and its preparation method | |
WO2008027600A2 (en) | Imatinib compositions | |
CA2644179C (en) | Novel pharmaceutical composition comprising a disintegration matrix | |
US20090324728A1 (en) | Pharmaceutical compositions comprising amorphous benzimidazole compounds | |
WO2015145462A1 (en) | Pharmaceutical compositions of dabigatran | |
WO2018153925A1 (en) | Stable pharmaceutical compositions comprising macitentan | |
JP2010519200A (en) | Controlled release formulation containing cilostazol and method for producing the same | |
KR101331723B1 (en) | Pharmaceutical compositions comprising a hcv polymerase inhibitor prodrug | |
US11234984B2 (en) | Solid dispersion | |
WO2019142207A1 (en) | Pharmaceutical compositions comprising ibrutinib | |
CN114096530A (en) | Pharmaceutical composition of compound and preparation method thereof | |
WO2013008253A2 (en) | Imatinib formulations | |
JP7046978B2 (en) | Compositions with improved water solubility and bioavailability | |
WO2023048684A2 (en) | The tablet comprising macitentan | |
EP4154873A1 (en) | The tablet comprising macitentan | |
WO2016012898A1 (en) | Oral pharmaceutical composition of lurasidone | |
WO2014115082A1 (en) | Pharmaceutical formulations of imatinib | |
KR102300335B1 (en) | Oral Formulation of Aprepitant | |
KR20220077094A (en) | Stability and bioavailability enhanced solid dispersion formulations of Olaparib | |
CA3094551C (en) | Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof | |
TR2021014838A2 (en) | TABLET CONTAINING MASITENTAN | |
WO2021106004A1 (en) | Pharmaceutical composition of s-adenosylmethionine | |
WO2023038600A1 (en) | A capsule formulation comprising macitentan | |
TR2021013983A1 (en) | A CAPSULE FORMULATION CONTAINING MACITENTAN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |